Perkidopa™

Levodopa & Carbidopa

COMPOSITION

Perkidopa™ 110 Tablet: Each tablet contains Levodopa USP 100 mg and Carbidopa 10 mg as Carbidopa Monohydrate USP.
Perkidopa™ 275 Tablet: Each tablet contains Levodopa USP 250 mg and Carbidopa 25 mg as Carbidopa Monohydrate USP.

PHARMACOLOGY

Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. Carbidopa inhibits decarboxylation of peripheral levodopa. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with levodopa makes more levodopa available for transport to the brain.

INDICATIONS

Perkidopa™ is indicated in the treatment of Parkinson's disease, post-encephalitic Parkinsonism, and symptomatic Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

DOSAGE & ADMINISTRATION

Usual Initial Dosage: The optimum daily dosage of **Perkidopa**™ must be determined by careful titration in each patient. If **Perkidopa**™110 is used, dosage may be initiated with one tablet three or four times a day. Dosage may be increased by one tablet every day or every other day until a total of eight tablets (2 tablets q.i.d.) is reached.
Maintenance dose: Therapy should be individualized & adjusted according to the desired therapeutic response. When more levodopa is required, **Perkidopa**™ 275 should be substituted for **Perkidopa**™110. If necessary, the dosage of **Perkidopa**™ 275 may be increased by one-half or one tablet every day or every other day to a maximum of eight tablets a day. Experience with total daily dosages of carbidopa greater than 200 mg is limited.

CONTRAINDICATION

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with Levodopa and carbidopa. These inhibitors must be discontinued at least two weeks prior to initiating therapy with Levodopa and carbidopa. Levodopa and carbidopa is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

PRECAUTIONS

Levodopa alone, as well as combination, is associated with dyskinesias. The occurrence of dyskinesias may require dosage reduction. It should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease.

ADVERSE REACTIONS

The most common adverse reactions reported with Levodopa and Carbidopa have included dyskinesias, such as choreiform, dystonic, and other involuntary movements, and nausea.

USE IN SPECIAL POPULATION

Pregnancy: Pregnancy Category: C. Nursing mother: Levodopa has been detected in human milk. Caution should be exercised when administered to a nursing woman. Pediatric Use: Use of the drug in patients below the age of 18 is not recommended.

STORAGE

Protect from light and moisture, store below 30°C. Keep the medicine out of the reach of children.

HOW SUPPLIED

Perkidopa™ 110 Tablet: Each box contains 30 tablets in blister pack.
Perkidopa™ 275 Tablet: Each box contains 30 tablets in blister pack.

Manufactured by

SQUARE
PHARMACEUTICALS LTD.
BANGLADESH